Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: BostonView who wrote (881)	4/13/2000 3:30:00 PM
From: Ian@SI	Read Replies (3) \| Respond to of 1321

Saw Elayne W and Tamara H at lunch today. Not only do we have the best AMD treatment in the world, we've got the most gorgeous IR department. ;^) CIBA has already shipped Visudyne today based upon the FDA approval last night. Anybody think that this approval might have been anticipated? [just a rhetorical question] Re offlabel usage: See Julian's post of the Nesbitt Burns report by Christine Charest. That contains a better and more complete answer than I could give you. But if I remember the numbers correctly, there's more than4 times as many offlabel candidates as those covered by the NDA. Presentation today focused on Visudyne. Barrett's Phase III data will be "unblinded" and presented this September. Approval may take less than 6 months after that. The Barrett's Population is about 30M worldwide. GURD patients, the targeted group, represent about 10% of theat total. So it seems to me that there's going to be a continuing stream of outstanding news coming from the QLTI pipeline. I think I'll hold my shares for at least another week or two. [g} Best wishes to all, Ian.